Environmental research · 2025
Prenatal exposure to a mixture of per- and polyfluoroalkyl substances (PFAS) and lung function and immune-related outcomes among males in childhood and young adulthood.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hull Sidsel Dan, Ferguson Kelly K, London Stephanie J, Hougaard Karin Sørig, Lindh Christian, Petersen Kajsa Ugelvig, Flachs Esben Meulengracht, Wise Lauren A, Wilcox Allen J, Liew Zeyan, Ramlau-Hansen Cecilia Høst, Toft Gunnar, Bonde Jens Peter, Tøttenborg Sandra Søgaard
Аннотация
BACKGROUND: Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) may influence lung and immune system development, but previous epidemiological studies are inconclusive and have not extended into young adulthood.
OBJECTIVE: To examine associations between prenatal exposure to a mixture of PFAS and respiratory and immune-related outcomes in a cohort of males.
METHODS: We studied 866 males with maternal pregnancy plasma measured for 15 PFAS, triclosan, and 10 phthalate metabolites used as a proxy for prenatal exposure. Spirometry was measured at approximately age 19 years. Asthma in young adulthood was reported in questionnaires at age 18 years. Asthma, hay fever, and eczema at 7 and 11 years of age were based on parental reports. We estimated the difference in spirometry measures and odds ratios (ORs) for questionnaire outcomes per one-interquartile range (IQR) increase in a mixture of seven well-detected PFAS using quantile g-computation models. Subsequently, we examined a mixture of seven PFAS, two phthalate metabolites and triclosan, and ran single-pollutant analyses.
RESULTS: A one-IQR increase in the PFAS mixture was associated with lower forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) (milliliter difference [95 % CI]: 85 [-160;-9], -88 [-173;-3], respectively), but not FEV1/FVC. Higher concentration of the PFAS mixture was also associated with lower odds of a history of and current hay fever (OR [95 % CI]: 0.52 [0.34; 0.80], 0.49 [0.30; 0.81], respectively), but not asthma or eczema. Associations did not change substantially when including phthalate metabolites and triclosan to the PFAS mixture and single-pollutant analyses were overall consistent with the mixture analyses.
CONCLUSION: Prenatal PFAS exposure was associated with lower FEV1 and FVC in a cohort of young adult males, suggesting an impact on lung development. Associations with reduced hay fever in childhood may suggest influences on immune maturation. Potential sex-specific effects should be addressed in future studies.
OBJECTIVE: To examine associations between prenatal exposure to a mixture of PFAS and respiratory and immune-related outcomes in a cohort of males.
METHODS: We studied 866 males with maternal pregnancy plasma measured for 15 PFAS, triclosan, and 10 phthalate metabolites used as a proxy for prenatal exposure. Spirometry was measured at approximately age 19 years. Asthma in young adulthood was reported in questionnaires at age 18 years. Asthma, hay fever, and eczema at 7 and 11 years of age were based on parental reports. We estimated the difference in spirometry measures and odds ratios (ORs) for questionnaire outcomes per one-interquartile range (IQR) increase in a mixture of seven well-detected PFAS using quantile g-computation models. Subsequently, we examined a mixture of seven PFAS, two phthalate metabolites and triclosan, and ran single-pollutant analyses.
RESULTS: A one-IQR increase in the PFAS mixture was associated with lower forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) (milliliter difference [95 % CI]: 85 [-160;-9], -88 [-173;-3], respectively), but not FEV1/FVC. Higher concentration of the PFAS mixture was also associated with lower odds of a history of and current hay fever (OR [95 % CI]: 0.52 [0.34; 0.80], 0.49 [0.30; 0.81], respectively), but not asthma or eczema. Associations did not change substantially when including phthalate metabolites and triclosan to the PFAS mixture and single-pollutant analyses were overall consistent with the mixture analyses.
CONCLUSION: Prenatal PFAS exposure was associated with lower FEV1 and FVC in a cohort of young adult males, suggesting an impact on lung development. Associations with reduced hay fever in childhood may suggest influences on immune maturation. Potential sex-specific effects should be addressed in future studies.